Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1992 2
1993 1
1994 1
1995 4
1996 1
1997 2
1998 5
1999 4
2000 3
2001 7
2002 5
2003 5
2004 4
2005 6
2006 4
2007 3
2008 4
2009 4
2010 3
2011 3
2012 8
2013 8
2014 3
2015 4
2016 3
2017 7
2018 5
2019 6
2020 3
2021 7
2022 8
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Among authors: hong rl. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL. Chan ATC, et al. Among authors: hong rl. Ann Oncol. 2023 Mar;34(3):251-261. doi: 10.1016/j.annonc.2022.12.007. Epub 2022 Dec 16. Ann Oncol. 2023. PMID: 36535566 Free article. Clinical Trial.
Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis.
Petit C, Lee A, Ma J, Lacas B, Ng WT, Chan ATC, Hong RL, Chen MY, Chen L, Li WF, Huang PY, Tan T, Ngan RKC, Zhu G, Mai HQ, Hui EP, Fountzilas G, Zhang L, Carmel A, Kwong DLW, Moon J, Bourhis J, Auperin A, Pignon JP, Blanchard P; MAC-NPC Collaborative Group. Petit C, et al. Among authors: hong rl. Lancet Oncol. 2023 Jun;24(6):611-623. doi: 10.1016/S1470-2045(23)00163-8. Lancet Oncol. 2023. PMID: 37269842
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma.
Lim DW, Kao HF, Suteja L, Li CH, Quah HS, Tan DS, Tan SH, Tan EH, Tan WL, Lee JN, Wee FY, Jain A, Goh BC, Chua MLK, Liao BC, Ng QS, Hong RL, Ang MK, Yeong JP, Iyer NG. Lim DW, et al. Among authors: hong rl. Nat Commun. 2023 May 15;14(1):2781. doi: 10.1038/s41467-023-38407-7. Nat Commun. 2023. PMID: 37188668 Free PMC article.
Corrigendum.
Koneru SL, Salinas H, Flores GE, Hong RL. Koneru SL, et al. Among authors: hong rl. Mol Ecol. 2016 Dec;25(24):6267. doi: 10.1111/mec.13924. Mol Ecol. 2016. PMID: 28035759 No abstract available.
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Rischin D, et al. Among authors: hong rl. Oral Oncol. 2022 May;128:105815. doi: 10.1016/j.oraloncology.2022.105815. Epub 2022 Apr 2. Oral Oncol. 2022. PMID: 35381576 Free article. Clinical Trial.
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Razak ARA, Wang HM, Chang JY, Ahn MJ, Munster P, Blumenschein G Jr, Solomon B, Lim DW, Hong RL, Pfister D, Saba NF, Lee SH, van Herpen C, Quadt C, Bootle D, Blumenstein L, Demanse D, Delord JP. Razak ARA, et al. Among authors: hong rl. Target Oncol. 2023 Nov;18(6):853-868. doi: 10.1007/s11523-023-00997-z. Epub 2023 Oct 25. Target Oncol. 2023. PMID: 37875771 Free PMC article. Clinical Trial.
Automated Cell Lineage Reconstruction using Label-Free 4D Microscopy.
Waliman M, Johnson RL, Natesan G, Tan S, Santella A, Hong RL, Shah PK. Waliman M, et al. Among authors: hong rl. bioRxiv [Preprint]. 2024 Jan 22:2024.01.20.576449. doi: 10.1101/2024.01.20.576449. bioRxiv. 2024. PMID: 38328064 Free PMC article. Preprint.
135 results